Major histocompatibility complex class II-tumor neoantigen complex (MHC II-neoantigen)

The Major histocompatibility complex class II-tumor neoantigen complex is a personalized molecular target consisting of a human leukocyte antigen (HLA) class II molecule and a peptide fragment derived from a tumor-specific somatic mutation (Alspach et al., 2019). These complexes are essential for the recognition of cancer cells by the adaptive immune system, specifically by CD4+ T helper cells (Tran et al., 2014). While MHC class II molecules are typically expressed on professional antigen-presenting cells, their expression can be induced on tumor cells, where they directly present neoantigens to the immune system (Frontiers in Immunology, 2024). The interaction between these complexes and T-cell receptors (TCRs) triggers the secretion of pro-inflammatory cytokines and coordinates the activity of cytotoxic CD8+ T cells (Nature, 2019). Therapeutic strategies such as neoantigen vaccines (e.g., mRNA-4157) and TCR-engineered T-cell therapies aim to exploit these complexes to elicit a potent and specific anti-tumor immune response (Cancers, 2023). However, challenges such as the accurate prediction of immunogenic neoantigens and the potential for tumor escape through HLA downregulation remain significant hurdles (NIH, 2018). This target represents a cornerstone of precision oncology, offering a pathway to highly individualized cancer treatments (BMC Genomics, 2018).

Other names

Patient-specific MHC class II molecules presenting tumor neoantigen peptidesHLA class II-neoantigen complexMHC-II neoepitopeTumor-specific MHC-II-peptide complextsMHC-II-neoantigen

Induction of neoantigen-specific CD4+ T cell activation and subsequent orchestration of a multi-effector anti-tumor immune response.